S&P Futures
4,165.00 +18.25 (+0.44%) Dow Futures
32,878.00 +121.00 (+0.37%) Nasdaq Futures
13,305.00 +76.25 (+0.58%) Russell 2000 Futures
1,930.10 +8.30 (+0.43%) Crude Oil
87.48 -1.53 (-1.72%) Gold
1,798.40 +7.20 (+0.40%)
Arcturus Therapeutics Holdings Inc. (ARCT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 20.64 |
| Open | 20.04 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 19.17 - 22.13 |
| 52 Week Range | 11.70 - 65.00 |
| Volume | |
| Avg. Volume | 639,561 |
| Market Cap | 584.652M |
| Beta (5Y Monthly) | 2.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.53 |
| Earnings Date | Aug 09, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.27 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ARCT
Related Research
- Arcturus Therapeutics HoldingsDaily – Vickers Top Buyers & Sellers for 08/13/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moatlast yearArgus Research
- Business Wire
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
SAN DIEGO, August 01, 2022--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter ended June 30, 2022 after the market close on Tuesday, August 9 and will also host a conference call and webcast at 4:30 pm
- Zacks
Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?
Zealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 22, 2022--Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
